{
  "metadata": {
    "case_id": 78,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T18:40:47.292998",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/78_NCT04568031.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/78_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.3,
          0.22
        ],
        [
          0.22,
          0.35
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.3,
          "status": "matched",
          "ref_item": {
            "label": "Part I",
            "type": "ACTIVE_COMPARATOR",
            "description": "Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.",
            "interventionNames": [
              "Drug: AZD1222"
            ]
          },
          "pred_item": {
            "label": "AZD1222",
            "type": "EXPERIMENTAL",
            "description": "Participants received two doses of AZD1222 (5 × 10^10 viral particles/dose) on Days 1 and 29, administered as intramuscular injections into the deltoid muscle.",
            "interventionNames": [
              "AZD1222"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.35,
          "status": "matched",
          "ref_item": {
            "label": "Part II",
            "type": "PLACEBO_COMPARATOR",
            "description": "Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.",
            "interventionNames": [
              "Drug: 0.9% (w/v) saline"
            ]
          },
          "pred_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants received two doses of placebo (saline; 0.9% weight/volume) on Days 1 and 29, administered as intramuscular injections into the deltoid muscle.",
            "interventionNames": [
              "Placebo"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.82,
          0.1
        ],
        [
          0.2,
          0.95
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "AZD1222",
            "description": "For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2",
            "armGroupLabels": [
              "Part I"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "AZD1222",
            "description": "Also known as ChAdOx1 nCoV-19. A replication-deficient simian adenovirus-vectored vaccine encoding the full-length SARS-CoV-2 spike protein.",
            "armGroupLabels": [
              "AZD1222"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "0.9% (w/v) saline",
            "description": "For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.",
            "armGroupLabels": [
              "Part II"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Saline (0.9% weight/volume).",
            "armGroupLabels": [
              "Placebo"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 5,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.96,
          0.05,
          0.05,
          0.08
        ],
        [
          0.05,
          0.82,
          0.65,
          0.3
        ],
        [
          0.08,
          0.86,
          0.4,
          0.28
        ],
        [
          0.1,
          0.68,
          0.96,
          0.45
        ],
        [
          0.12,
          0.15,
          0.4,
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay",
            "description": "Seroresponse is a binary outcome where a success is when the fold rise in titers compared with baseline is \\>= 4. The fold rise in titers was calculated as the ratio of the post-vaccination titer level to the baseline titer level. The percentage of participants with a post-vaccination seroresponse (\\>= 4-fold rise in titers from Day 1 baseline value to Day 57) to the S antigen of AZD1222 as measured by MSD serology assay is reported.",
            "timeFrame": "Baseline (Day 1) and Day 57"
          },
          "pred_item": {
            "measure": "Anti-SARS-CoV-2 spike seroresponse",
            "description": "Measured by anti-SARS-CoV-2 spike seroresponse, defined as a ≥4-fold rise in titre from Day 1 baseline value.",
            "timeFrame": "Day 57"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With Local Solicited Adverse Events (AE)",
            "description": "Solicited AEs are local or systemic predefined AEs for reactogenicity assessment. Participants were given an axillary thermometer, tape measure, and access to app for the solicited AE eDiary, with instructions on use, along with the emergency 24-hour telephone number to contact the on-call study physician if needed. Participants were instructed to record for 7 days following administration of each dose of AZD1222, the timing and severity of local and systemic solicited AEs, if applicable, and whether medication was taken to relieve the symptoms.",
            "timeFrame": "From Day 1 up to 7 days post each dose of study vaccination, approximately 14 days"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With Systemic Solicited AEs",
            "description": "Solicited AEs are local or systemic predefined AEs for reactogenicity assessment. Participants were given an axillary thermometer, tape measure, and access to app for the solicited AE eDiary, with instructions on use, along with the emergency 24-hour telephone number to contact the on-call study physician if needed. Participants were instructed to record for 7 days following administration of each dose of AZD1222, the timing and severity of local and systemic solicited AEs, if applicable, and whether medication was taken to relieve the symptoms.",
            "timeFrame": "From Day 1 up to 7 days post each dose of study vaccination, approximately 14 days"
          },
          "pred_item": {
            "measure": "Solicited local and systemic reactogenicity",
            "description": "Occurrence of solicited local and systemic reactogenicity signs/symptoms.",
            "timeFrame": "6 days after each dose"
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 2,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With AEs, Serious AEs (SAE) and Adverse Event of Special Interest (AESI) Occurring Post Each Dose of Study Vaccination",
            "description": "An AE is the development of any untoward medical occurrence in a clinical study participant administered medicinal product and which does not necessarily have a causal relationship with this medicinal product. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is an AE occurring during any study phase that fulfils one or more of the following criteria: death; immediately life-threatening; in-participant hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital abnormality or birth defect; an important medical event. The AESIs were events of scientific and medical interest specific to the further understanding of the study vaccination safety profile and required close monitoring and rapid communication by the investigators to the sponsor.",
            "timeFrame": "From Day 1 up to 28 days post each dose of study vaccination, approximately 57 days"
          },
          "pred_item": {
            "measure": "Unsolicited Adverse Events (AEs), Serious AEs (SAEs), and AEs of Special Interest (AESIs)",
            "description": "Occurrence of unsolicited AEs, SAEs, and AESIs.",
            "timeFrame": "28 days after each dose"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 3,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters",
            "description": "Clinical laboratory values were evaluated for each laboratory parameter as applicable including hematology and clinical chemistry. The baseline was defined as the last non-missing measurement taken prior to the first dose of study vaccination (including unscheduled measurements, if any).",
            "timeFrame": "From Day 1 up to 28 days post each dose of study vaccination, approximately 57 days"
          },
          "pred_item": {
            "measure": "Safety laboratory measures",
            "description": "Change from baseline in safety laboratory measures including haemoglobin concentration, leukocyte count, platelet count and clinical chemistry.",
            "timeFrame": "Days 1, 8, 29, 36 and 57"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 7,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.86,
          0.78,
          0.02
        ],
        [
          0.72,
          0.93,
          0.02
        ],
        [
          0.68,
          0.9,
          0.08
        ],
        [
          0.9,
          0.78,
          0.08
        ],
        [
          0.7,
          0.84,
          0.06
        ],
        [
          0.72,
          0.86,
          0.06
        ],
        [
          0.05,
          0.08,
          0.97
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Seroresponse to the Receptor-Binding Domain (RBD) Antigen of AZD1222 as Measured by MSD Serology Assay",
            "description": "Seroresponse is a binary outcome where a success is when the fold rise in titers compared with baseline is \\>= 4. The fold rise in titers was calculated as the ratio of the post-vaccination titer level to the baseline titer level. The percentage of participants with a post-vaccination seroresponse (\\>= 4-fold rise in titers from Day 1 baseline value to Day 57) to the RBD antigen of AZD1222 as measured by MSD serology assay is reported.",
            "timeFrame": "Baseline (Day 1) and Day 57"
          },
          "pred_item": null
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "measure": "Geometric Mean Titers (GMTs) for SARS-CoV-2 S and RBD Antibodies as Measured by MSD Serology Assay",
            "description": "The GMT was calculated as the antilogarithm of Σ(log base 2 transformed titer/n), i.e. as the anti-logarithm transformation of the mean of the log-transformed titer, where 'n' is the number of participants with titer information.",
            "timeFrame": "Baseline (Day 1) and Days 15, 29, 43, 57, 183, and 365"
          },
          "pred_item": {
            "measure": "Geometric Mean Titre (GMT) and Geometric Mean Fold Rise of immunogenicity",
            "description": "GMT and geometric mean fold rise of immunogenicity against SARS-CoV-2 spike and RBD antigens and SARS-CoV-2 nAb.",
            "timeFrame": "At each time point up to Day 365"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Geometric Mean Fold Rise (GMFR) for SARS-CoV-2 S and RBD Antibodies as Measured by MSD Serology Assay",
            "description": "The fold rise was calculated as the ratio of the post-vaccination titer level to the baseline titer level, where baseline was defined as the last measurement taken before the first dose of study vaccination. The GMFR was calculated as anti-logarithm of Σ (log base 2 transformed (post-vaccination titer/ pre-vaccination titer)/n). Where 'n' is the number of participants with titer information.",
            "timeFrame": "Baseline (Day 1) and Days 15, 29, 43, 57, 183, and 365"
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With Seroresponse to SARS-CoV-2 Neutralizing Antibodies (nAb) of AZD1222 as Measured by Pseudo-Neutralization Assay",
            "description": "Seroresponse is a binary outcome where a success is when the fold rise in titers compared with baseline is \\>= 4. The fold rise in titers was calculated as the ratio of the post-vaccination titer level to the baseline titer level. The percentage of participants with a post-vaccination seroresponse (\\>= 4-fold rise in titers from Day 1 baseline value to Day 57) to SARS-CoV-2 nAb of AZD1222 as measured by pseudo-neutralization assay is reported.",
            "timeFrame": "Baseline (Day 1) and Day 57"
          },
          "pred_item": {
            "measure": "Seroresponse for RBD antigen and SARS-CoV-2 nAb",
            "description": "Proportion of participants with a seroresponse for the receptor-binding domain (RBD) antigen and SARS-CoV-2 neutralizing antibody (nAb).",
            "timeFrame": "Day 57 (28 days after the second dose)"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "GMTs for SARS-CoV-2 nAb as Measured by Pseudo-Neutralization Assay",
            "description": "The GMT was calculated as the antilogarithm of Σ(log base 2 transformed titer/n), i.e. as the anti-logarithm transformation of the mean of the log-transformed titer, where 'n' is the number of participants with titer information.",
            "timeFrame": "Baseline (Day 1) and Days 29, 57, 183, and 365"
          },
          "pred_item": null
        },
        {
          "ref_idx": 5,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "GMFR for SARS-CoV-2 nAb as Measured by Pseudo-Neutralization Assay",
            "description": "The fold rise was calculated as the ratio of the post-vaccination titer level to the baseline titer level, where baseline was defined as the last measurement taken before the first dose of study vaccination. The GMFR was calculated as anti-logarithm of Σ (log base 2 transformed (post-vaccination titer/ pre-vaccination titer)/n). Where 'n' is the number of participants with titer information.",
            "timeFrame": "Baseline (Day 1) and Days 29, 57, 183, and 365"
          },
          "pred_item": null
        },
        {
          "ref_idx": 6,
          "pred_idx": 2,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With SAEs and AESIs Occurring Throughout the Study",
            "description": "An SAE is an AE occurring during any study phase that fulfils one or more of the following criteria: death; immediately life-threatening; in-participant hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital abnormality or birth defect; an important medical event. The AESIs were events of scientific and medical interest specific to the further understanding of the study vaccination safety profile and required close monitoring and rapid communication by the investigators to the sponsor.",
            "timeFrame": "From Day 1 up to final DCO of 17 January 2022, up to a maximum of 365 days"
          },
          "pred_item": {
            "measure": "Occurrence of SAEs and AESIs",
            "description": "Long-term monitoring of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs).",
            "timeFrame": "Up to Day 365"
          }
        }
      ]
    }
  ]
}